<!DOCTYPE html>
<html>
<head>
<title>CytoDyn Inc. Quarterly report pursuant to Section 13 or 15(d)</title>
<link href="/investors/stylesheets/ir.stockpr.css" rel="stylesheet" type="text/css">
<script type="text/javascript" src="/investors/javascripts/ir.js"></script>
<link rel="stylesheet" type="text/css" href="https://ir.stockpr.com/stylesheets/xbrl.css">
<script type="text/javascript" src="https://ir.stockpr.com/javascripts/xbrl.min.js"></script>
<script type="text/javascript" src="https://ir.stockpr.com/javascripts/xbrl.js"></script>
</head>
<body>
<style>
body {
font-family: Arial, Helvetica, sans-serif;
font-size: 12px;
color: #454545;
}
</style>
<div class="xbrl-content">
    <h3>Quarterly report pursuant to Section 13 or 15(d)</h3>
    <div id="xbrl-menu-top">
        <div class="navigation">
            <ul class="xbrl-sf-menu">
                
                    <li>
                        <a class="menu-item " href="/investors/sec-filings/quarterly-reports/xbrl_doc_only/5971">Cover</a>
                        <ul class="submenu">
                                                            <li><a href="/investors/sec-filings/quarterly-reports/xbrl_doc_only/5971">Cover Page</a></li>
                                                    </ul>
                    </li>
                                    <li>
                        <a class="menu-item " href="/investors/sec-filings/quarterly-reports/xbrl_doc_only/5972">Financial Statements</a>
                        <ul class="submenu">
                                                            <li><a href="/investors/sec-filings/quarterly-reports/xbrl_doc_only/5972">Consolidated Balance Sheets</a></li>
                                                            <li><a href="/investors/sec-filings/quarterly-reports/xbrl_doc_only/5973">Consolidated Balance Sheets (Parenthetical)</a></li>
                                                            <li><a href="/investors/sec-filings/quarterly-reports/xbrl_doc_only/5974">Consolidated Statements of Operations</a></li>
                                                            <li><a href="/investors/sec-filings/quarterly-reports/xbrl_doc_only/5975">Consolidated Statements of Cash Flows</a></li>
                                                            <li><a href="/investors/sec-filings/quarterly-reports/xbrl_doc_only/5976">Consolidated Statement of Changes in Stockholders' (Deficit) Equity</a></li>
                                                    </ul>
                    </li>
                                    <li>
                        <a class="menu-item " href="/investors/sec-filings/quarterly-reports/xbrl_doc_only/5977">Notes to Financial Statements</a>
                        <ul class="submenu">
                                                            <li><a href="/investors/sec-filings/quarterly-reports/xbrl_doc_only/5977">Organization</a></li>
                                                            <li><a href="/investors/sec-filings/quarterly-reports/xbrl_doc_only/5978">Summary of Significant Accounting Policies</a></li>
                                                            <li><a href="/investors/sec-filings/quarterly-reports/xbrl_doc_only/5979">Recent Accounting Pronouncements</a></li>
                                                            <li><a href="/investors/sec-filings/quarterly-reports/xbrl_doc_only/5980">Convertible Instruments</a></li>
                                                            <li><a href="/investors/sec-filings/quarterly-reports/xbrl_doc_only/5981">Derivative Liabilities</a></li>
                                                            <li><a href="/investors/sec-filings/quarterly-reports/xbrl_doc_only/5982">Stock Options and Warrants</a></li>
                                                            <li><a href="/investors/sec-filings/quarterly-reports/xbrl_doc_only/5983">Acquisition of Patents and Intangibles</a></li>
                                                            <li><a href="/investors/sec-filings/quarterly-reports/xbrl_doc_only/5984">License Agreements</a></li>
                                                            <li><a href="/investors/sec-filings/quarterly-reports/xbrl_doc_only/5985">Commitments and Contingencies</a></li>
                                                            <li><a href="/investors/sec-filings/quarterly-reports/xbrl_doc_only/5986">Public Warrant Tender Offerings</a></li>
                                                            <li><a href="/investors/sec-filings/quarterly-reports/xbrl_doc_only/5987">Registered Direct Equity Offerings</a></li>
                                                            <li><a href="/investors/sec-filings/quarterly-reports/xbrl_doc_only/5988">Employee Benefit Plan</a></li>
                                                            <li><a href="/investors/sec-filings/quarterly-reports/xbrl_doc_only/5989">Related Party Transactions</a></li>
                                                            <li><a href="/investors/sec-filings/quarterly-reports/xbrl_doc_only/5990">Subsequent Events</a></li>
                                                    </ul>
                    </li>
                                    <li>
                        <a class="menu-item " href="/investors/sec-filings/quarterly-reports/xbrl_doc_only/5991">Accounting Policies</a>
                        <ul class="submenu">
                                                            <li><a href="/investors/sec-filings/quarterly-reports/xbrl_doc_only/5991">Summary of Significant Accounting Policies (Policies)</a></li>
                                                    </ul>
                    </li>
                                    <li>
                        <a class="menu-item current" href="/investors/sec-filings/quarterly-reports/xbrl_doc_only/5992">Notes Tables</a>
                        <ul class="submenu">
                                                            <li><a href="/investors/sec-filings/quarterly-reports/xbrl_doc_only/5992">Summary of Significant Accounting Policies (Tables)</a></li>
                                                            <li><a href="/investors/sec-filings/quarterly-reports/xbrl_doc_only/5993">Convertible Instruments (Tables)</a></li>
                                                            <li><a href="/investors/sec-filings/quarterly-reports/xbrl_doc_only/5994">Derivative Liabilities (Tables)</a></li>
                                                            <li><a href="/investors/sec-filings/quarterly-reports/xbrl_doc_only/5995">Stock Options and Warrants (Tables)</a></li>
                                                            <li><a href="/investors/sec-filings/quarterly-reports/xbrl_doc_only/5996">Acquisition of Patents and Intangibles (Tables)</a></li>
                                                    </ul>
                    </li>
                                    <li>
                        <a class="menu-item " href="/investors/sec-filings/quarterly-reports/xbrl_doc_only/5997">Notes Details</a>
                        <ul class="submenu">
                                                            <li><a href="/investors/sec-filings/quarterly-reports/xbrl_doc_only/5997">Summary of Significant Accounting Policies - Additional Information (Detail)</a></li>
                                                            <li><a href="/investors/sec-filings/quarterly-reports/xbrl_doc_only/5998">Liability Measured at Fair Value on Recurring Basis by Level within Fair Value Hierarchy (Detail)</a></li>
                                                            <li><a href="/investors/sec-filings/quarterly-reports/xbrl_doc_only/5999">Reconciliation of Liability Measured at Fair Value on Recurring Basis Using Significant Unobservable Inputs (Level 3) (Detail)</a></li>
                                                            <li><a href="/investors/sec-filings/quarterly-reports/xbrl_doc_only/6000">Convertible Instruments - Additional Information (Detail)</a></li>
                                                            <li><a href="/investors/sec-filings/quarterly-reports/xbrl_doc_only/6001">Warrants At Relative Fair Value and Beneficial Conversion Feature at Intrinsic Value (Details)</a></li>
                                                            <li><a href="/investors/sec-filings/quarterly-reports/xbrl_doc_only/6002">Activity Related to Notes (Detail 1)</a></li>
                                                            <li><a href="/investors/sec-filings/quarterly-reports/xbrl_doc_only/6003">Derivative Liability - Additional Information (Detail)</a></li>
                                                            <li><a href="/investors/sec-filings/quarterly-reports/xbrl_doc_only/6004">Summary of Fair Value Warrant Derivative Liability and Related Common Shares (Detail)</a></li>
                                                            <li><a href="/investors/sec-filings/quarterly-reports/xbrl_doc_only/6005">Assumptions used in Estimating Fair Value of Warrant Derivative Liability (Detail)</a></li>
                                                            <li><a href="/investors/sec-filings/quarterly-reports/xbrl_doc_only/6006">Summary of Fair Value of Convertible Note Redemption Provision Derivative Liability (Detail)</a></li>
                                                            <li><a href="/investors/sec-filings/quarterly-reports/xbrl_doc_only/6007">Assumptions used in Estimating Fair Value of Convertible Note Redemption Provision Derivative Liability (Detail)</a></li>
                                                            <li><a href="/investors/sec-filings/quarterly-reports/xbrl_doc_only/6008">Stock Options and Warrants - Additional Information (Detail)</a></li>
                                                            <li><a href="/investors/sec-filings/quarterly-reports/xbrl_doc_only/6009">Stock Options and Warrants (Detail)</a></li>
                                                            <li><a href="/investors/sec-filings/quarterly-reports/xbrl_doc_only/6010">Acquisition of Patents and Intangibles - Additional Information (Detail)</a></li>
                                                            <li><a href="/investors/sec-filings/quarterly-reports/xbrl_doc_only/6011">Summary of the Net Purchase Price and Allocation to the Acquired Assets (Detail)</a></li>
                                                            <li><a href="/investors/sec-filings/quarterly-reports/xbrl_doc_only/6012">Intangible Assets Activity (Detail)</a></li>
                                                            <li><a href="/investors/sec-filings/quarterly-reports/xbrl_doc_only/6013">License Agreements - Additional Information (Detail)</a></li>
                                                            <li><a href="/investors/sec-filings/quarterly-reports/xbrl_doc_only/6014">Commitments and Contingencies - Additional Information (Detail)</a></li>
                                                            <li><a href="/investors/sec-filings/quarterly-reports/xbrl_doc_only/6015">Public Warrant Tender Offerings - Additional Information (Detail)</a></li>
                                                            <li><a href="/investors/sec-filings/quarterly-reports/xbrl_doc_only/6016">Registered Direct Equity Offerings - Additional Information (Detail)</a></li>
                                                            <li><a href="/investors/sec-filings/quarterly-reports/xbrl_doc_only/6017">Employee Benefit Plan - Additional Information (Detail)</a></li>
                                                            <li><a href="/investors/sec-filings/quarterly-reports/xbrl_doc_only/6018">Related Party Transactions - Additional Information (Detail)</a></li>
                                                            <li><a href="/investors/sec-filings/quarterly-reports/xbrl_doc_only/6019">Subsequent Events - Additional Information (Detail)</a></li>
                                                    </ul>
                    </li>
                            </ul>
        </div>
    </div>
    <div class="spr-xbrl-document">
        <h4>Convertible Instruments (Tables)</h4>
                <div style="clear:both;"></div>
    </div>
</div>
</body>
</html>